476 related articles for article (PubMed ID: 24568523)
1. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy.
Li QQ; Lu ZH; Yang L; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li J; Li Y; Shen L
Asian Pac J Cancer Prev; 2014; 15(2):945-50. PubMed ID: 24568523
[TBL] [Abstract][Full Text] [Related]
2. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
[TBL] [Abstract][Full Text] [Related]
3. The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma.
Chen C; Sun P; Dai QS; Weng HW; Li HP; Ye S
PLoS One; 2014; 9(11):e112581. PubMed ID: 25393117
[TBL] [Abstract][Full Text] [Related]
4. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
5. Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer.
Huang Z; Liu Y; Yang C; Li X; Pan C; Rao J; Li N; Liao W; Lin L
BMC Cancer; 2018 May; 18(1):515. PubMed ID: 29720123
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
[TBL] [Abstract][Full Text] [Related]
7. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.
Chen L; Chen Y; Zhang L; Xue Y; Zhang S; Li X; Song H
Pathol Oncol Res; 2021; 27():1609811. PubMed ID: 34712105
[No Abstract] [Full Text] [Related]
8. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
He CB; Lin XJ
PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Baseline Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Local and Advanced Gastric Cancer Patients.
Aldemir MN; Turkeli M; Simsek M; Yildirim N; Bilen Y; Yetimoglu H; Bilici M; Tekin SB
Asian Pac J Cancer Prev; 2015; 16(14):5933-7. PubMed ID: 26320475
[TBL] [Abstract][Full Text] [Related]
10. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS.
Yang J; Guo X; Wang M; Ma X; Ye X; Lin P
Sci Rep; 2017 Dec; 7(1):17166. PubMed ID: 29215037
[TBL] [Abstract][Full Text] [Related]
12. Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio in predicting survival for patients with stage I-II gastric cancer.
Sun X; Liu X; Liu J; Chen S; Xu D; Li W; Zhan Y; Li Y; Chen Y; Zhou Z
Chin J Cancer; 2016 Jun; 35(1):57. PubMed ID: 27342313
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer.
Jeong JH; Lim SM; Yun JY; Rhee GW; Lim JY; Cho JY; Kim YR
Oncology; 2012; 83(5):292-9. PubMed ID: 22964877
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study.
Inal A; Kaplan MA; Kuçukoner M; Urakci Z; Guven M; Nas N; Yunce M; Işikdogan A
Asian Pac J Cancer Prev; 2012; 13(8):3869-72. PubMed ID: 23098485
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Systemic Inflammatory Response Biomarkers in Patients Receiving Chemotherapy for Unresectable and Recurrent Advanced Gastric Cancer.
Namikawa T; Munekage E; Munekage M; Maeda H; Yatabe T; Kitagawa H; Kobayashi M; Hanazaki K
Oncology; 2016; 90(6):321-6. PubMed ID: 27225990
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study.
Inamoto S; Kawada K; Okamura R; Hida K; Sakai Y
Int J Colorectal Dis; 2019 Jul; 34(7):1303-1315. PubMed ID: 31177316
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, neutrophil-platelet score and prognostic nutritional index: do they have prognostic significance in metastatic pancreas cancer?
Dogan M; Algin E; Guven ZT; Baykara M; Kos TF; Bal O; Zengin N
Curr Med Res Opin; 2018 May; 34(5):857-863. PubMed ID: 29161926
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
Turkeli M; Aldemir MN; Cayir K; Simsek M; Bilici M; Tekin SB; Yildirim N; Bilen N; Makas I
Asian Pac J Cancer Prev; 2015; 16(3):985-9. PubMed ID: 25735393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
